ARTICLE | Company News
Amgen submits etelcalcetide NDA
August 26, 2015 2:05 AM UTC
Amgen Inc. (NASDAQ:AMGN) submitted an NDA to FDA for etelcalcetide ( AMG 416) to treat secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD) on hemodialysis. The IV peptid...